Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has ... HW_Technical Insights" report to their offering. ... in the Health and Wellness sector and has identified ... impact in the year 2015. The research service provides ... and wellness technologies that are anticipated to have the ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
... Thoratec Corporation,(Nasdaq: THOR ), a world ... and restore failing hearts, said today that it will,be ... on,Wednesday, January 14. , Gary ... on the company, beginning at 9 a.m., Pacific Standard ...
... 6 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix for the endocrinology, ... receipt of $5.5 million from Baxter Healthcare Corporation ... the terms of its HYLENEX licensing agreement, which ...
... 6 The Susan G. Komen for the ... in Indianapolis has partnered with,BioStorage Technologies, Inc. (BST) ... will store a third of the tissue bank,s ... including,samples being collected during the tissue bank,s upcoming ...
Cached Biology Technology:BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 2BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 3
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Greenland ice sheet can experience extreme melting even when temperatures ... Dr. Marco Tedesco, assistant professor in the Department of Earth ... His findings suggest that glaciers could undergo a self-amplifying ... halt. "We are finding that even if you don,t ...
... of us would love nothing more than to trick ourselves into ... a new brain imaging study reported in the November issue of ... just be a way. The key is to go with our ... findings suggest that a simple hormone-inspired pill could be the long-sought ...
... -- With salmonella-tainted ground turkey sickening more than 100 ... ability to detect outbreaks of food-borne illness and determine ... A new approach, reported online Oct. 14 in the ... collaborative team led by Cornell University scientists, will enable ...
Cached Biology News:Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3Simple gut hormone combo makes our brains think we're full 2New test can precisely pinpoint food pathogens 2
... FANCM ( Abpromise for all tested ... peptide derived from within residues 2000 to ... the amino acid sequence is proprietary) ... .) Entrez GeneID: ...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: